Results 1 to 10 of about 1,610 (149)

Hormonal Approach for Postmenopausal Vulvovaginal Atrophy [PDF]

Frontiers in Reproductive Health, 2021
Menopause is a physiological and progressive phenomenon secondary to decreased ovarian follicular reserve that significantly affects the genital tract. Although postmenopausal vulvovaginal atrophy primarily affects postmenopausal women, it is also seen ...
Ana Paula Ferreira Costa, Ayane Cristine Alves Sarmento, Pedro Vieira-Baptista, Pedro Vieira-Baptista, José Eleutério, Ricardo Ney Cobucci, Ana Katherine Gonçalves, Ana Katherine Gonçalves   +7 more
doaj   +6 more sources

Use of Moisturizers and Lubricants for Vulvovaginal Atrophy [PDF]

Frontiers in Reproductive Health, 2021
The estrogen decrease in postmenopausal women results in functional and anatomical changes in the genitourinary tract. The most prevalent and bothersome symptoms are vaginal dryness, dyspareunia, and reduced lubrication, which can significantly affect ...
Ayane Cristine Alves Sarmento, Márcia Farina Kamilos, Ana Paula Ferreira Costa, Pedro Vieira-Baptista, Pedro Vieira-Baptista, José Eleutério, Ana Katherine Gonçalves, Ana Katherine Gonçalves   +7 more
doaj   +6 more sources

GRACE-trial: a randomised active-controlled trial for vulvovaginal atrophy in patients with breast cancer on endocrine therapy – study protocol [PDF]

BMJ Open, 2023
Introduction Breast cancer is the most common cancer type in women worldwide. Due to hormone receptor positivity in the majority of the breast cancer tumours is endocrine therapy a crucial part in the treatment landscape of breast cancer.
Glenn Vergauwen, Hannelore Denys, Piet Cools, Hans Verstraelen, Koen van de Vijver, Tom Fiers, Liv Veldeman   +6 more
doaj   +2 more sources

Vulvovaginal Atrophy Following Treatment for Oncogynecologic Pathologies: Etiology, Epidemiology, Diagnosis, and Treatment Options [PDF]

Medicina
Vulvovaginal atrophy, characterized by the thinning of vaginal mucosa typically resulting from reduced estrogen levels, is frequently exacerbated by oncogynecologic treatments such as chemotherapy, hormonal therapy, radiotherapy, or surgery.
Ramunė Narutytė, Guoda Žukienė, Daiva Bartkevičienė   +2 more
doaj   +2 more sources

Fractional CO2 Laser for Treatment of Vulvovaginal Atrophy: A Short Time Follow-up [PDF]

Journal of Family and Reproductive Health, 2020
Objective: The aim of this study was to evaluate the safety and efficacy of fractional CO2 laser for treatment of vulvovaginal atrophy. Materials and methods: In this clinical trial study, we evaluated the laser effect on vulvovaginal atrophy in 47 women
Zinat Ghanbari, Samira Sohbati, Tahereh Eftekhar, Leyla Sahebi, Soodabeh Darvish, Safa Alasiri, Maryam Deldar Pasikhani   +6 more
doaj   +2 more sources

Lubricants application in vulvovaginal atrophy [PDF]

РМЖ. Мать и дитя, 2018
Lubricants application in vulvovaginal atrophy Yu.E. Dobrokhotova, S.A. Khlynova Pirogov Russian National Research Medical University, Moscow, Russian Federation Interim periods as well as the postmenopausal period are extremely important in ...
Yu.E. Dobrokhotova, S.A. Khlynova
doaj   +2 more sources

Comment on Jankovic et al. Understanding the Benefits of CO₂ Laser Treatment for Vulvovaginal Atrophy. Medicina 2024, 60, 1059 [PDF]

Medicina
We write with concerns regarding the recent publication of “Understanding the Benefits of CO2 Laser Treatment for Vulvovaginal Atrophy” [...]
Catherine Broomfield, Fiona Li, Jason Abbott   +2 more
doaj   +2 more sources

Topical Spermidine Hyaluronate (Spd-HA) in Vulvovaginal Atrophy: A Preliminary Study [PDF]

Medicina
Background and Objectives: Genitourinary syndrome of menopause (GSM), previously termed vulvovaginal atrophy (VVA), is a prevalent hypoestrogenic condition characterized by genital, sexual, and urinary symptoms. Although hormonal therapies are effective,
Irene Porcari, Michela Carena Maini, Carlo Angelo Ghisalberti, Caterina Tezze, Erica Trimarchi, Alessandra Graziottin, Mariachiara Bosco, Chiara Casprini, Simone Garzon, Stefano Uccella   +9 more
doaj   +2 more sources

Impact Of Vulvovaginal Atrophy Of Menopause In Spanish Women: Prevalence And Symptoms According To The EVES Study [PDF]

Sexual Medicine, 2019
Introduction: The prevalence of menopausal women with confirmed vulvovaginal atrophy (VVA) oscillates between 67–98%. Aim: To assess the prevalence of postmenopausal women with VVA confirmed by gynecologic clinical assessment among all women attending ...
Santiago Palacios, MD, PhD, Silvia P. González, MD, PhD, Micaela Fernández-Abellán, MD, Montserrat Manubens, MD, PhD, Pascual García-Alfaro, MD, C.Argudo Prieto, L.Baquedano Mainar, J.Calleja Abu-Amshah, M.J.Cancelo Hidalgo, C. Castelo-Branco i Flores, P.Coronado Martin, M.Correa Rancel, M.Fernández Abellán, J.M.Fernández Moya, P.García Alfaro, M.González Fernández, S.González Rodríguez, E.Iglesias Bravo, P.Llaneza Coto, M.Manubens Grau, P.Marín Sánchez, N.Mendoza Ladrón de Guevara, B.Otero García-Ramos, S. Palacios, J.C.Presa Lorite, R.Sánchez Borrego, S.Sánchez Méndez, F.Vázquez Fernández   +27 more
doaj   +2 more sources

Vulvovaginal atrophy: modern approaches to diagnostics and management

Zaporožskij Medicinskij Žurnal
The aim of the review is to analyze the latest data on the current state of diagnosis and management of a common benign vulvar and vaginal disease in postmenopausal women – atrophic vulvovaginitis.
V. H. Siusiuka, N. V. Avramenko, M. I. Pavliuchenko, M. Yu. Serhiienko, A. O. Kniazieva   +4 more
doaj   +4 more sources